Reference is made to the announcement made on 27 October 2023 regarding the transfer of 1,900,219 shares in Medistim ASA from Aeternum Capital AS to its 100% owned subsidiary, Acapital MEDI HoldCo AS (“HoldCo”), by way of a capital contribution in kind.
As part of requests for in-specie redemption in Aeternum Capital AS by certain of its investors, a capital reduction in Aeternum Capital AS has been resolved by way of a distribution in kind of 8,154,977 shares in HoldCo from Aeternum Capital AS to the investors which have requested redemption, equal to approx. 81.55% of the votes and capital in HoldCo. The creditor notice period for such capital reduction expired today. The transfer of the shares in HoldCo will occur upon registration of the capital reduction with the Norwegian Business Registry, expected to occur in early 2024.
…
Vis børsmeldingen
As part of the redemption, 7,980,813 shares in HoldCo are distributed from Aeternum Capital AS to WQZ Investment Group Ltd., equal to approx. 79.81% of the votes and capital in HoldCo.
Following the transfer of the shares in HoldCo, WQZ Investment Group Ltd. will be the majority shareholder with controlling voting rights in HoldCo and will be the indirect holder of the 1,900,219 shares in Medistim ASA, equal to approx. 10.36% of the shares and votes in Medistim ASA.
Aeternum Capital AS and other companies managed by Aeternum Management AS will be a minority shareholder in HoldCo and will as such no longer have indirect control over the shares held by HoldCo in Medistim ASA.
Aeternum Capital AS is managed by Aeternum Management AS, while WQZ Investment Group Ltd. is indirectly controlled by trusts established by John Fredriksen for the benefit of his family.
No other rights to shares in Medistim ASA are held directly or indirectly by any of the above mentioned entities.
Aeternum Capital AS is a closely associated person of Anthea Arff-Pettersen, board member and primary insider in Medistim ASA. Please see attached form for further details.
This information is subject to the disclosure requirements pursuant to Article 19 of the EU Market Abuse Regulation and Sections 4-2, cf. 5-12 of the Norwegian Securities Trading Act.
Kilde
